Emblem Corp To Disrupt $60 Billion Opiod Market With Cannabis Based Sustained Release Formulation

Very big news out of Emblem Corp $EMC.V today, with the halt on this news event lifted tomorrow morning at 5AM PST Oct 4th… This is one to watch:

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

PARIS, Ontario, Oct. 03, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”) announced today that it has entered into a Collaboration and Licensing Agreement (the “Agreement”) with Canntab Therapeutics Limited (“Canntab”) of Toronto. Canntab has developed a patent-pending oral sustained release formulation for cannabinoids (the “Sustained Release Product” or the “Product”). Under the Agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of the Sustained Release Product.

Full Release:

http://emblemcorp.com/blog/emblem-announces-exclusive-agreement-canntab-therapeutics-cannabinoid-based-oral-sustained-release-formulation/

 

Dave Doherty

President & CEO

Rockshield Capital

www.rockshield.ca

604-315-1237

TSXV: EMC

Leave a Reply

Your email address will not be published. Required fields are marked *